Immunotec received two Gold Globee Awards at the 16th Annual 2026 Globee Awards for Business. Both Gold awards were given as “Best of Category” honors to recognize the company’s achievements in business growth and life sciences innovation. These awards include:
- Achievement in Rapid Growth & Scaling – Gold Globee Winner, Best of Category
Recognizing a period of significant business transformation, global expansion and financial performance that reinforces core operations - HealthTech, Life Sciences or Biotech Product or Service of the Year – Gold Globee Winner, Best of Category
Given for the company’s flagship product Immunocal and honoring three decades of science-driven innovation
The company increased its annual revenue from $145 million in 2023 to $200 million in 2025, with EBITDA growth from $10 million to almost $25 million, which the company believes demonstrates its ability to translate revenue growth into stronger profitability.
“These two awards represent something we’re incredibly proud of: our ability to grow as a global business while staying true to the science that has defined Immunotec for nearly three decades,” said Mauricio Domenzain, Immunotec Chief Executive Officer. “Our success has never been about growth alone. It’s about building a stronger company, continuing to advance the research behind Immunocal and creating lasting value for the people and communities we serve. This recognition is a testament to the dedication of our entire global team and the independent consultants who help bring our mission to life every day.”
